WO2010009210A3 - Acetylsalicyclic acid derivatives useful to treat metabolic syndromes - Google Patents

Acetylsalicyclic acid derivatives useful to treat metabolic syndromes Download PDF

Info

Publication number
WO2010009210A3
WO2010009210A3 PCT/US2009/050660 US2009050660W WO2010009210A3 WO 2010009210 A3 WO2010009210 A3 WO 2010009210A3 US 2009050660 W US2009050660 W US 2009050660W WO 2010009210 A3 WO2010009210 A3 WO 2010009210A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
treat metabolic
acid derivatives
derivatives useful
metabolic syndromes
Prior art date
Application number
PCT/US2009/050660
Other languages
French (fr)
Other versions
WO2010009210A2 (en
Inventor
Amol Tendolkar
Anandan Palani
Xianhai Huang
Robert G. Aslanian
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of WO2010009210A2 publication Critical patent/WO2010009210A2/en
Publication of WO2010009210A3 publication Critical patent/WO2010009210A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

The present invention provides compounds of the Formula I: (I) wherein G represents a hydrolysable or metabolizable linker group; and R represents a recoverable residue of a nicotinic acid receptor agonist; and salts, solvates, esters and prodrugs thereof, as well as pharmaceutical compositions containing them, and methods of using them to treat metabolic syndrome, dyslipidemia, cardiovascular diseases, disorders of the peripheral and central nervous system, hematological diseases, cancer, inflammation, respiratory diseases, gastroenterological diseases, diabetes, and non-alcoholic fatty liver diseases.
PCT/US2009/050660 2008-07-17 2009-07-15 Acetylsalicyclic acid derivatives useful to treat metabolic syndromes WO2010009210A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8156608P 2008-07-17 2008-07-17
US61/081,566 2008-07-17

Publications (2)

Publication Number Publication Date
WO2010009210A2 WO2010009210A2 (en) 2010-01-21
WO2010009210A3 true WO2010009210A3 (en) 2010-06-03

Family

ID=41449976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/050660 WO2010009210A2 (en) 2008-07-17 2009-07-15 Acetylsalicyclic acid derivatives useful to treat metabolic syndromes

Country Status (3)

Country Link
AR (1) AR072813A1 (en)
TW (1) TW201016667A (en)
WO (1) WO2010009210A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011296737A1 (en) 2010-08-31 2013-04-11 Snu R&Db Foundation Use of the fetal reprogramming of a PPAR delta agonist
CA2942050A1 (en) * 2014-03-13 2015-09-17 Barry D. Sears Compositions and methods for reducing chronic low-level inflammation
CN105017170A (en) * 2015-07-13 2015-11-04 佛山市赛维斯医药科技有限公司 Cyanobenzotriazole sulfoxide 11 beta-HSD1 inhibitors and use thereof
CN104910083A (en) * 2015-07-13 2015-09-16 佛山市赛维斯医药科技有限公司 Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof
CN104987312A (en) * 2015-07-13 2015-10-21 佛山市赛维斯医药科技有限公司 Aminobenzene triazole sulfoxide 11 beta-HSD1 inhibitor and application thereof
CN105001171A (en) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 Nitrobenzene triazole sulphoxides 11[beta]-HSD1 inhibitor and application of same
CN104910084A (en) * 2015-07-13 2015-09-16 佛山市赛维斯医药科技有限公司 Terminal amido replaced triazole sulfoxide, preparation method and application thereof
CN104987313A (en) * 2015-07-13 2015-10-21 佛山市赛维斯医药科技有限公司 Terminal-substituted triazole sulfoxide compound, preparation method thereof and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2392008A1 (en) * 1977-05-02 1978-12-22 Fabre Sa Pierre Ester(s) of hydroxyalkyl pyridine carboxylic amide(s) - with pharmaceutically active acid(s) showing enhanced activity
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO2006124490A2 (en) * 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2009080795A1 (en) * 2007-12-21 2009-07-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Efficient aspirin prodrugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2392008A1 (en) * 1977-05-02 1978-12-22 Fabre Sa Pierre Ester(s) of hydroxyalkyl pyridine carboxylic amide(s) - with pharmaceutically active acid(s) showing enhanced activity
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO2006124490A2 (en) * 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2009080795A1 (en) * 2007-12-21 2009-07-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Efficient aspirin prodrugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEBER, DIETER: "Reactions of heterocycles containing the 2-acyl-2-propenone structure. IV. Synthesis of pyridine derivatives from 4-hydroxy-2-oxo-2H-chromene-3-carboxaldehydes and enamines", 1987, ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) , 320(5), 445-50 CODEN: ARPMAS; ISSN: 0365-6233, XP002576669 *
SHAH V R ET AL: "STUDIES ON NICOTINAMIDE DERIVATIVES: PART-1: N1-P-(NICOTINAMIDOBENZOYL)-N3-SUBSTITUTED BENZOYL HYDRAZINES", JOURNAL OF THE INSTITUTION OF CHEMISTS (INDIA), CALCUTTA, IN, vol. 68, no. PART 01, 1 January 1996 (1996-01-01), pages 23/24, XP000943008, ISSN: 0020-3254 *

Also Published As

Publication number Publication date
AR072813A1 (en) 2010-09-22
WO2010009210A2 (en) 2010-01-21
TW201016667A (en) 2010-05-01

Similar Documents

Publication Publication Date Title
WO2010009210A3 (en) Acetylsalicyclic acid derivatives useful to treat metabolic syndromes
GEP20135919B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
EA200970524A1 (en) DERIVATIVES OF AZACYCLOALKANES AS INHIBITORS STEAROIL COFERMENT AND DELTA-9 DESATURASES
WO2011056985A3 (en) Substituted heterocyclic compounds
WO2009069032A3 (en) Novel glucocorticoid receptor agonists
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
WO2010004578A3 (en) Novel and improved processes for the preparation of paliperidone
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
MA32479B1 (en) Compounds new active as muscarinic receptor antagonists
AR072814A1 (en) NIACINA DERIVATIVES, NICOTINIC ACID RECEIVER AGONISTS (NAR), USEFUL TO TREAT METABOLIC SYNDROMES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GEP20135804B (en) Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
WO2009027785A3 (en) 1, 3-oxazole derivatives as cetp inhibitors
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
WO2007143014A3 (en) Methods for preparing glutamic acid derivatives and intermediates thereof
GEP20094745B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same
WO2008002853A3 (en) Phenylacetic acid derivatives as cox-2 inhibitors
WO2008049996A3 (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09790451

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09790451

Country of ref document: EP

Kind code of ref document: A2